Cystatin C as a Promising Biomarker of Atherosclerotic Plaque

Shojiro Sawada

Division of Metabolism and Diabetes, Tohoku Medical and Pharmaceutical University, Sendai, Japan

See article vol. 28: 506-513

Complex atherosclerotic lesions of the aorta, including those of the aortic arch and descending aorta are challenging. When performing surgery for aortic aneurysm, the preoperative assessment of atherosclerotic plaque in the aorta is important to minimize embolic complications affecting the brain and distal organs. However, biomarkers for aortic plaque have not yet been fully investigated.

In this issue of the Journal of Atherosclerosis and Thrombosis, Nishimura Y et al. examined the association of serum cystatin C levels with aortic plaques of the descending aorta in patients scheduled to undergo surgery for aortic arch aneurysm. Nishimura Y et al. assessed the quantity and quality of descending aorta plaques using the Hounsfield unit (HU) method of computed tomography angiography (CTA). They revealed the following novel findings. First, soft plaque volume of the descending aorta in patients with chronic kidney disease (CKD) was higher than in those without CKD. Second, serum cystatin C levels correlated with the total and soft plaque volumes of the descending aorta in those without CKD. Notably, however, serum creatinine levels had no correlation with any types of plaque volume. Third, soft plaque volume was higher in patients with high cystatin C level (>0.95 mg/L) than in those with low cystatin C level (≤0.95 mg/L), despite normal renal function (eGFR ≥ 60 mL/min/1.73m²).

Cystatin C is a protein encoded by the CST3 gene and is a cysteine protease inhibitor produced by all nucleated cells at a constant rate; it is found in all tissues and body fluids. Cystatin C plays an important role in the atherosclerotic process, i.e., inhibiting the cathepsin-dependent proteolytic activity in the vascular wall. The remodeling of the extracellular matrix (ECM) in the vascular wall is an important feature of the atherosclerosis pathogenesis. The imbalance between cathepsin and cystatin C in vascular local sites may result in increased degradation of ECM, leading to the development of an atherosclerotic plaque. Indeed, human pathological studies have shown increased cathepsin and decreased cystatin C expressions in atherosclerotic lesions.

In clinical practice, serum cystatin C level is a well-established biomarker of the kidney function (filtration). Because cystatin C is a low-molecular-weight protein (13 kDa) consisting 120 amino acids, it is freelyfiltrated at the glomerulus, fully reabsorbed and catabolized, but not secreted, by the nephron tubule. Moreover, cystatin C is less influenced by age, gender, or muscle mass. Thus, serum cystatin C level is believed to be a more accurate biomarker than serum creatinine level for the estimation of kidney function.

Beyond its clinical use as a biomarker of kidney function, serum cystatin C level has been shown to be a superior predictor of cardiovascular disease compared to serum creatinine level. Several epidemiological studies consistently reported that the increased serum cystatin C levels were associated with the development of cardiovascular event or mortality. Shlipak MG et al. reported a cohort study of 4,637 elderly people living in the community. On comparison with the two lowest quintiles combined (serum cystatin C level, ≤0.99 mg/l), the highest quintile of cystatin C (≥1.29 mg/l) was associated with a significantly elevated risk of death from cardiovascular causes (hazard ratio, 2.27; 95% confidence interval=1.73–2.97), myocardial infarction (hazard ratio, 1.48; 95% confidence interval=1.08–2.02), and stroke (hazard ratio, 1.47 95%; confidence interval=1.08–2.02).
level was associated with total and soft plaque volumes using CTA in patients without CKD (eGFR ≥ 60 mL/min/1.73m²). Altogether, several epidemiological studies have consistently documented the positive association between serum cystatin C level and atherosclerotic disease.

The discrepancy between the increased serum cystatin C levels in cardiovascular disease in numerous epidemiological studies and decreased tissue cystatin C levels in atherosclerotic plaques in pathological studies remain unsolved (Fig. 1). Atherosclerosis is an inflammatory disease characterized by remodeling of ECM of the arterial walls. Tissue cystatin C levels are reduced against proteolytic activity of cathepsin within atherosclerotic plaque. Inflammatory cytokine stimulates cells to produce cystatin C for systemic circulation, thus presumably compensating for the decreased cystatin C levels in atherosclerotic plaques. The above description is only a hypothesis, and further studies are needed to examine whether this hypothesis is correct.

**Conflict of Interest**
None.

**References**

1) Nishimura Y, Honda K, Yuzaki M, Tajima K, Nakamura
7) Lee M, Saver JL, Huang WH, Chow J, Chang KH and Ovbiagele B: Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ Cardiovasc Qual Outcomes, 2010; 3: 675-683
8) Koenig W, Twardella D, Brenner H and Rothenbacher D: Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem, 2005; 51: 321-327
9) Gu FF, Lu SZ, Chen YD, Zhou YJ, Song XT, Jin ZN and Liu H: Relationship between plasma cathepsin S and cystatin C levels and coronary plaque morphology of mild to moderate lesions: an in vivo study using intravascular ultrasound. Chin Med J, 2009; 122: 2820-2826
10) Král A, Kovárník T, Vaníčková Z, Skalická H, Horák J, Bayerová K, Chen Z, Wahle A, Zhang L, Kopřiva K, Benáková H, Sonka M and Linhart A: Cystatin C Is Associated with the Extent and Characteristics of Coronary Atherosclerosis in Patients with Preserved Renal Function. Folia Biol (Praha), 2016; 62: 225-234
11) Wen Y, Xia D, Wang Y, Zhang H, Li H, Ali G, Gao Y, Li J, Sun W and Li L: Cystatin C is Associated With Plaque Phenotype and Plaque Burden. Kidney Blood Press Res, 2016; 41: 197-207